Rocket Pharmaceuticals (RCKT) Stock Statistics & Valuation Metrics

Rocket Pharmaceuticals has a market cap or net worth of $363.63M. The enterprise value is $166.01M.

Rocket Pharmaceuticals has 108,222,230 shares outstanding. The number of shares has decreased by -2.65% in one year.

Rocket Pharmaceuticals’s return on equity (ROE) is -0.56 and return on invested capital (ROIC) is -55.45%.

The current PE Ratio of Rocket Pharmaceuticals is ―. Rocket Pharmaceuticals’s PEG ratio is 0.71.

In the last 12 months, Rocket Pharmaceuticals had revenue of 0.00 and earned -258.75M in profits. Earnings per share was -2.73.

In the last 12 months, operating cash flow was -202.15M and capital expenditures -669.00K, giving a free cash flow of -202.82M billion.

Rocket Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Rocket Pharmaceuticals upcoming earnings date is Mar 2, 2026, Before Open (Confirmed).

Rocket Pharmaceuticals as a current ratio of 9.30, with Debt / Equity ratio of 7.98%

In the past 12 months, Rocket Pharmaceuticals has paid 0.00 in taxes.

Rocket Pharmaceuticals EV to EBITDA ratio is -4.26, with an EV/FCF ratio of -4.89.

Rocket Pharmaceuticals has $222.76M in cash and marketable securities with $25.05M in debt, giving a net cash position of $197.71M billion.

Gross margin is -10.18%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Rocket Pharmaceuticals is $9.83, which is 11.43% higher than the current price. The consensus rating is Moderate Buy